Triamcinolone regulated apopto-phagocytic gene expression patterns in the clearance of dying retinal pigment epithelial cells. A key role of Mertk in the enhanced phagocytosis

Biochim Biophys Acta. 2015 Feb;1850(2):435-46. doi: 10.1016/j.bbagen.2014.10.026. Epub 2014 Oct 27.

Abstract

Background: The apopto-phagocytic gene expression patterns during clearance of dying cells in the retina and the effect of triamcinolone (TC) upon these processes have relevance to development of age-related macular degeneration (AMD).

Methods: ARPE-19 cells and primary human retinal pigment epithelium (hRPE) were induced to undergo cell death by anoikis and the clearance of these cells by living hRPE/ARPE-19 or human monocyte-derived macrophages (HMDMs) in the presence or absence of TC was quantified by flow cytometry. TaqMan low-density gene expression array determining known markers of phagocytosis and loss-of-function studies on selected apopto-phagocytic genes was carried out in HMDM engulfing anoikic cells.

Results: The glucocorticoid TC had a profound phagocytosis-enhancing effect on HMDM engulfing anoikic ARPE-19 or hRPE cells, causing a selective upregulation of the Mer tyrosine kinase (MERTK) receptor, while decreasing the expression of the AXL receptor tyrosine kinase and thrombospondin-1 (THSB-1). The key role of the MERTK could be demonstrated in HMDM engulfing dying cells using gene silencing as well as blocking antibodies. Similar pathways were found upregulated in living ARPE-19 engulfing anoikic ARPE-19 cells. Gas6 treatment enhanced phagocytosis in TC-treated HMDMs.

Conclusions: Specific agonists of the Mertk receptor may have a potential role as phagocytosis enhancers in the retina and serve as future targets for AMD therapy.

General significance: The use of Gas6 as enhancer of retinal phagocytosis via the MerTK receptor, alone or in combination with other specific ligands of the tyrosine kinase receptors' family may have a potential role in AMD therapy.

Keywords: AMD; Anoikis; Gas6; MERTK; Phagocytosis; Triamcinolone.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anoikis / drug effects*
  • Anoikis / genetics
  • Anti-Inflammatory Agents / pharmacology*
  • Antibodies, Neutralizing / pharmacology
  • Cell Line
  • Epithelial Cells / cytology
  • Epithelial Cells / enzymology*
  • Eye Proteins / biosynthesis*
  • Eye Proteins / genetics
  • Female
  • Gene Expression Regulation, Enzymologic / drug effects*
  • Gene Expression Regulation, Enzymologic / genetics
  • Gene Silencing / drug effects
  • Humans
  • Macrophages / cytology
  • Macrophages / metabolism*
  • Macular Degeneration / drug therapy
  • Macular Degeneration / enzymology
  • Macular Degeneration / genetics
  • Male
  • Phagocytosis / drug effects*
  • Phagocytosis / genetics
  • Proto-Oncogene Proteins / biosynthesis*
  • Proto-Oncogene Proteins / genetics
  • Receptor Protein-Tyrosine Kinases / biosynthesis*
  • Receptor Protein-Tyrosine Kinases / genetics
  • Retinal Pigment Epithelium / cytology
  • Retinal Pigment Epithelium / enzymology*
  • Triamcinolone / pharmacology*
  • c-Mer Tyrosine Kinase

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Neutralizing
  • Eye Proteins
  • Proto-Oncogene Proteins
  • Triamcinolone
  • MERTK protein, human
  • Receptor Protein-Tyrosine Kinases
  • c-Mer Tyrosine Kinase